{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:18:27Z","timestamp":1783023507208,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["tC2020_03_MED"],"award-info":[{"award-number":["tC2020_03_MED"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["CS-2017-17- 007"],"award-info":[{"award-number":["CS-2017-17- 007"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Biomedical Research Centre"},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aristo"},{"DOI":"10.13039\/501100014756","name":"Hexal AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014756","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015756","name":"Janssen-Cilag","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GH Research"},{"DOI":"10.13039\/501100014751","name":"neuraxpharm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014751","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shire International GmbH"},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013410","name":"LivaNova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40263-021-00837-6","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T11:03:00Z","timestamp":1626778980000},"page":"881-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8475-8972","authenticated-orcid":false,"given":"Vera M.","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrin","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-6952","authenticated-orcid":false,"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4647-8088","authenticated-orcid":false,"given":"James","family":"Rucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-859X","authenticated-orcid":false,"given":"Michael","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Findeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4286-5830","authenticated-orcid":false,"given":"Philipp","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"837_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11920-019-0997-0","volume":"21","author":"J Rehm","year":"2019","unstructured":"Rehm J, Shield KD. Global burden of disease and the impact of mental and addictive disorders. Curr Psychiatry Rep. 2019;21:10.","journal-title":"Curr Psychiatry Rep"},{"key":"837_CR2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"837_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"837_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","volume":"175","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson ST, Ballard ED, Ph D, Bloch MH, Mathew SJ. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175:150\u20138.","journal-title":"Am J Psychiatry"},{"key":"837_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.biopsych.2009.04.029","volume":"66","author":"RB Price","year":"2009","unstructured":"Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry Society of Biological Psychiatry. 2009;66:522\u20136.","journal-title":"Biol Psychiatry. Society of Biological Psychiatry"},{"key":"837_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiat. 2018;75:139\u201348.","journal-title":"JAMA Psychiat"},{"key":"837_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiat. 2019;76:893\u2013903.","journal-title":"JAMA Psychiat"},{"key":"837_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","volume":"22","author":"M Fedgchin","year":"2019","unstructured":"Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22:616\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"key":"837_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176:428\u201338.","journal-title":"Am J Psychiatry"},{"key":"837_CR10","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.euroneuro.2018.11.1016","volume":"29","author":"E Wajs","year":"2019","unstructured":"Wajs E, Leah A, Morrison R, Daly E, Lane R, Lim P, et al. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study. Eur Neuropsychopharmacol. 2019;29:S44\u20135.","journal-title":"Eur Neuropsychopharmacol"},{"key":"837_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","volume":"28","author":"R Ochs-Ross","year":"2020","unstructured":"Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression\u2014TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28:121\u201341.","journal-title":"Am J Geriatr Psychiatry"},{"key":"837_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23:801\u201311.","journal-title":"Mol Psychiatry"},{"key":"837_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","volume":"5","author":"B Short","year":"2018","unstructured":"Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5:65\u201378. https:\/\/doi.org\/10.1016\/S2215-0366(17)30272-9.","journal-title":"Lancet Psychiatry"},{"key":"837_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1055\/s-0034-1365945","volume":"82","author":"S K\u00f6hler","year":"2014","unstructured":"K\u00f6hler S, St\u00f6ver LA, Bschor T. MAO-Hemmer als Behandlungsoption der therapieresistenten Depression: Anwendung, Wirksamkeit und Besonderheiten. Fortschritte der Neurol Psychiatr. 2014;82:228\u201338.","journal-title":"Fortschritte der Neurol Psychiatr."},{"key":"837_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JCP.0000000000001153","volume":"40","author":"S Ulrich","year":"2020","unstructured":"Ulrich S, Ricken R, Buspavanich P, Schlattmann P, Adli M. Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in the treatment of depression: a systematic review and comprehensive meta-analysis. J Clin Psychopharmacol. 2020;40:63\u201374.","journal-title":"J Clin Psychopharmacol"},{"key":"837_CR16","unstructured":"Janssen Pharmaceutica NV. Spravato EPAR Product information [Internet]. Sprav. EPAR Prod. Inf. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spravato#product-information-section. Accessed 30 July 2020."},{"key":"837_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/0952-8180(90)90078-H","volume":"2","author":"DJ Doyle","year":"1990","unstructured":"Doyle DJ. Ketamine induction and monoamine oxidase inhibitors. J Clin Anesth. 1990;2:324\u20135.","journal-title":"J Clin Anesth"},{"key":"837_CR18","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.euroneuro.2015.07.021","volume":"25","author":"L Bartova","year":"2015","unstructured":"Bartova L, Vogl SE, Stamenkovic M, Praschak-Rieder N, Naderi-Heiden A, Kasper S, et al. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: a report of two cases. Eur Neuropsychopharmacol. 2015;25:2183\u20134.","journal-title":"Eur Neuropsychopharmacol"},{"key":"837_CR19","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/JCP.0000000000001281","volume":"40","author":"H Bottemanne","year":"2020","unstructured":"Bottemanne H, Bonnard E, Claret A, Petit AC, Gaillard R, Fossati P. Ketamine and monoamine oxidase inhibitor combination: utility, safety, efficacy? J Clin Psychopharmacol. 2020;40:636\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"837_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.genhosppsych.2018.05.007","volume":"54","author":"RB Katz","year":"2018","unstructured":"Katz RB, Toprak M, Wilkinson ST, Sanacora G, Ostroff R. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: a letter to the editor. Gen Hosp Psychiatry. 2018;54:62\u20134.","journal-title":"Gen Hosp Psychiatry"},{"key":"837_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.npbr.2020.02.008","volume":"36","author":"DL Dunner","year":"2020","unstructured":"Dunner DL, Fugate RM, Demopulos CM. Safety and efficacy of esketamine nasal spray in a depressed patient who was being treated with tranylcypromine: a case report. Neurol Psychiatry Brain Res. 2020;36:30\u20131.","journal-title":"Neurol Psychiatry Brain Res"},{"key":"837_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/JCP.0000000000001244","volume":"40","author":"JCC Wang","year":"2020","unstructured":"Wang JCC, Swainson J. The concurrent treatment with intravenous ketamine and an irreversible monoamine oxidase inhibitor for treatment-resistant depression without hypertensive crises. J Clin Psychopharmacol. 2020;40:515\u20137. https:\/\/doi.org\/10.1097\/JCP.0000000000001244.","journal-title":"J Clin Psychopharmacol"},{"key":"837_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/a-0991-0582","volume":"53","author":"P Ritter","year":"2020","unstructured":"Ritter P, Findeis H, Bauer M. Ketamine in the treatment of depressive episodes. Pharmacopsychiatry. 2020;53:45\u201350.","journal-title":"Pharmacopsychiatry"},{"key":"837_CR24","first-page":"2284","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Blood Press. 2018;36:2284\u2013309.","journal-title":"Blood Press"},{"key":"837_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4088\/JCP.13m08852","volume":"76","author":"LB Wan","year":"2015","unstructured":"Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76:247\u201352.","journal-title":"J Clin Psychiatry"},{"key":"837_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jad.2018.02.025","volume":"236","author":"P Riva-Posse","year":"2018","unstructured":"Riva-Posse P, Reiff CM, Edwards JA, Job GP, Galendez GC, Garlow SJ, et al. Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. J Affect Disord. 2018;236:291\u20137.","journal-title":"J Affect Disord"},{"key":"837_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/acps.12572","volume":"134","author":"CK Loo","year":"2016","unstructured":"Loo CK, G\u00e1lvez V, O\u2019Keefe E, Mitchell PB, Hadzi-Pavlovic D, Leyden J, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016;134:48\u201356.","journal-title":"Acta Psychiatr Scand"},{"key":"837_CR28","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1177\/0269881120922955","volume":"34","author":"LC Del Sant","year":"2020","unstructured":"Del Sant LC, Sarin LM, Magalh\u00e3es EJM, Lucchese AC, Tuena MA, Nakahira C, et al. Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression. J Psychopharmacol. 2020;34:1155\u201362.","journal-title":"J Psychopharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00837-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00837-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00837-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:35:54Z","timestamp":1628613354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00837-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00837-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"14 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This report represents independent research supported by Bundesministerium f\u00fcr Bildung und Forschung (BMBF) grant tC2020_03_MED (transCampus\/TUD\/BMBF), as well as the National Institute for Health Research (AHY and NIHR Clinician Scientist Award JR CS-2017-17- 007) and\u00a0NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London. PR received grants from the BMBF. The views expressed are those of the author(s) and not necessarily those of the BMBF, NHS, NIHR, or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AHY gave paid lectures and is on advisory boards for the following companies: AstraZeneca, Eli Lilly, Lundbeck, Sunovion, Servier, LivaNova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, and COMPASS and serves as a consultant to Johnson & Johnson and LivaNova. JR was paid by COMPASS Pathways to attend trial-related meetings and conferences to present the results of research using psilocybin and served as a paid consultant to Beckley PsyTech and Clerkenwell Health. MB has received institutional funding\/grant support from Deutsche Forschungsgemeinschaft (DFG), BMBF, and the European Commission; has received speaker honoraria and\/or travel compensation from Aristo, Hexal AG, Janssen Pharmaceutica NV, Janssen-Cilag, and Sunovion; has served on advisory boards or received honoraria consultancy from GH Research, Janssen-Cilag, neuraxpharm, Novartis, Sandoz, Shire International GmbH, Sumitomo Dainippon, Sunovion, and Takeda. The authors assert that the mentioned companies had no influence over the content of this article. VML, CS, HF, and PR have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our study complies with the Declaration of Helsinki and the study protocol was approved by the local ethics committee of the Medical Faculty of the Technical University Dresden (EK 263052019).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable, as anonymized routine clinical data were used.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The dataset can be obtained from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"SPSS Syntax codes are available upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study design and interpretation of the data. Material preparation and data collection were performed by VML and HF, and data analysis was performed by CS and VML. The first draft of the manuscript was written by VML; all authors commented on subsequent versions of the manuscript and approved the final manuscript and the decision to submit it for publication. All authors agree to be accountable for the data reported in the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}